Table 2.
Remission rates among patients treated with venetoclax and azacitidine combination.
| FLT3 mutated | FLT3-ITD | FLT3-ITD AR < 0.5 | FLT3-ITD AR ≥ 0.5 | FLT3-TKD | FLT3 wild type | FLT3-ITD and NPM1 | FLT3-ITD and NMP1 wild type | |
|---|---|---|---|---|---|---|---|---|
| (n = 42) | (n = 30) | (n = 21) | (n = 9) | (n = 13) | (n = 238) | (n = 10) | (n = 19) | |
| CR rate, n (%) | 16 (38.1) | 9 (30.0) | 8 (38.1) | 1 (11.1) | 7 (53.8) | 96 (40.3) | 3 (30.0) | 6 (31.6) |
| CR + CRi, n (%) | 28 (66.7) | 19 (63.3) | 14 (66.7) | 5 (55.6) | 10 (76.9) | 159 (66.8) | 7 (70.0) | 11 (57.9) |
| Duration of CR + CRi (months), median (95% CI) | 17.3 (10.1–NE) | 17.3 (4.6–NE) | 21.0 (3.0–NE) | NR (7.4–NE) | 15.9 (2.8–NE) | 18.4 (15.1–NE) | NR (4.6–NE) | 10.1 (1.8–NE) |
| Time to the 1st response, (months), median (range) | 1.2 (0.8–7.7) | 1.2 (0.8–4.8) | 1.2 (0.9–4.6) | 1.2 (0.8–4.8) | 1.2 (1.0–7.7) | 1.3 (0.7–9.9) | 1.2 (1.0–1.9) | 1.0 (0.8–4.8) |
| CR + CRi by initiation of C-2, n (%) | 21 (50.0) | 16 (53.3) | 12 (57.1) | 4 (44.4) | 6 (46.2) | 97 (40.8) | 6 (60.0) | 9 (47.4) |
| Post-baseline transfusion independence ratea, n (%) | 25 (59.5) | 17 (56.7) | 11 (52.4) | 6 (66.7) | 8 (61.5) | 135 (56.7) | 7 (70.0) | 9 (47.4) |
Note: CR was defined as absolute neutrophil count >103/μL, platelets >105/μL, red cell transfusion independence (TI) for at least 8 weeks, and bone marrow with <5% blasts; CRi is defined as all criteria for CR, except for neutropenia ≤103/μL or thrombocytopenia ≤105/μL.
Abbreviations: AR, allelic ratio; CR, complete remission; CRi, CR+ incomplete hematologic recovery; NE, not evaluable; NR, not reached.
aPost-baseline transfusion independence is defined as a period of at least 56 days with no red blood cell or platelet transfusion during the evaluation period.